Logo

Ventyx Biosciences Reports Preclinical Data of VTX3232 in Murine Diet-Induced Obesity Models

Share this

Ventyx Biosciences Reports Preclinical Data of VTX3232 in Murine Diet-Induced Obesity Models

Shots:

  • Ventyx reported data from 2 preclinical diet-induced obesity (DIO) mice studies where DIO Study 1 assessed VTX3232 & semaglutide alone vs standard diet & DIO vehicle (high-fat diet) controls while DIO Study 2 assessed VTX3232 + semaglutide. The P-IIa trial is expected in H2’24
  • Study 1 showed reduced body weight & food intake, decreased liver steatosis & triglycerides, improved cardiometabolic parameters (reduced cholesterol, insulin resistance, fasting blood glucose, HbA1c) & reduced systemic inflammatory biomarkers (IL-1β, IL-6, fibrinogen)
  • Study 2 depicted higher benefits in body weight, liver steatosis & metabolic parameters, decreased systemic inflammatory biomarkers & improvement in body composition (reduced fat mass & increased lean mass percentage)

Ref: Ventyx | Image: Ventyx

Related News:- Ventyx Biosciences Reports P-II Trial Results of VTX002 for Moderate-to-Severely Active Ulcerative Colitis

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions